Lorundrostat Lowered Blood Pressure and Urine Protein in Kidney Disease Patients in Company-Funded Trial Ahead of FDA Decision
In a company-sponsored trial, lorundrostat lowered blood pressure and urine albumin in kidney disease patients. The FDA decides by Dec. 22.
Medical Daily ·